Last reviewed · How we verify
Placebo to Telmisartan
Placebo to Telmisartan is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Novartis. It is currently FDA-approved for Hypertension, Cardiovascular risk reduction in patients with hypertension.
Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.
Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Cardiovascular risk reduction in patients with hypertension.
At a glance
| Generic name | Placebo to Telmisartan |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues. By blocking angiotensin II signaling, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload. This mechanism also provides renal protection and cardiovascular benefits beyond blood pressure reduction.
Approved indications
- Hypertension
- Cardiovascular risk reduction in patients with hypertension
Common side effects
- Dizziness
- Upper respiratory tract infection
- Back pain
- Pharyngitis
- Hyperkalemia
- Hypotension
Key clinical trials
- Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (PHASE3)
- A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension (PHASE3)
- Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension (PHASE3)
- SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (PHASE4)
- Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment (PHASE3)
- Health Evaluation in African Americans Using RAS Therapy (PHASE1, PHASE2)
- Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension (PHASE3)
- Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Telmisartan CI brief — competitive landscape report
- Placebo to Telmisartan updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Placebo to Telmisartan
What is Placebo to Telmisartan?
How does Placebo to Telmisartan work?
What is Placebo to Telmisartan used for?
Who makes Placebo to Telmisartan?
What drug class is Placebo to Telmisartan in?
What development phase is Placebo to Telmisartan in?
What are the side effects of Placebo to Telmisartan?
What does Placebo to Telmisartan target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Cardiovascular risk reduction in patients with hypertension
- Compare: Placebo to Telmisartan vs similar drugs
- Pricing: Placebo to Telmisartan cost, discount & access